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abstract
Multiple sclerosis is a complex neurodegenerative disease, thought to arise through autoimmunity
against antigens of the central nervous system. The autoimmunity hypothesis fails to explain why
genetic and environmental risk factors linked to the disease in one population tend to be unimportant
in other populations. Despite great advances in documenting the cell and molecular mechanisms
underlying MS pathophysiology, the autoimmunity framework has also been unable to develop a
comprehensive explanation of the etiology of the disease. I propose a new framework for understanding
MS as a dysfunction of the metabolism of lipids. Specifically, the homeostasis of lipid metabolism
collapses during acute-phase inflammatory response triggered by a pathogen, trauma, or stress,
starting a feedback loop of increased oxidative stress, inflammatory response, and proliferation of
cytoxic foam cells that cross the blood brain barrier and both catabolize myelin and prevent remyelination. Understanding MS as a chronic metabolic disorder illuminates four aspects of disease onset
and progression: 1) its pathophysiology; 2) genetic susceptibility; 3) environmental and pathogen
triggers; and 4) the skewed sex ratio of patients. It also suggests new avenues for treatment.

Introduction
ULTIPLE SCLEROSIS (MS) is an inflammatory autoimmune disease of
the central nervous system (CNS) that results
in the demyelination of neurons. It affects
approximately 1.3 million people around
the world, with high prevalence concentrated in northern latitudes. It also affects
women more than men at an approximate
ratio of 2:1, although men tend to have a
more severe course of the disease. Several genetic and environmental factors have been as-

M

sociated with the risk of developing the disease,
although the influence of external factors on
the genetic background of patients is not currently fully understood. Definite triggers of the
onset of MS, and the molecular mechanisms
underlying them, have also proved elusive. MS
is perceived as a disease of autoimmunity
against antigens of the central nervous system
(Greer and McCombe 2011). This framework, the autoimmune hypothesis, revolves
around mechanisms of the immune system,
such as the autoreactivity of T cells to CNS
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antigens, linkage of immune-relevant genes
to MS patients, and the influence of Vitamin
D on immune response (Challoner et al.
1995; Kim et al. 2006; McCoy et al. 2006;
Ascherio and Munger 2007; Broadley 2007;
Cantorna 2008; Fensterl and Sen 2009; Ramagopalan et al. 2009; Ascherio et al. 2010;
Beretich and Beretich 2010; Grant 2010;
Lünemann et al. 2010; Greer and McCombe
2011).
Environmental and genetic MS risk factors have been analyzed in the context of
immune system function. Dietary intake
and/or UV synthesis Vitamin D3, for example, regulates the immune system and lowers
the incidence of MS (Ramagopalan et al.
2009). This, however, does not explain the
relatively high incidence of MS in regions
where populations can obtain Vitamin D
both through UV synthesis and/or diet, such
as Iran or Japan (Yamasaki et al. 1996; Niino
et al. 2002; Maghzi et al. 2010). Another set
of proposed MS triggers is exposure to certain pathogens, such as the Epstein-Barr virus (EBV) (Lünemann et al. 2010). Again,
the autoimmune framework fails to explain
why genetically similar populations exposed
to similar pathogens have drastically different incidence of the disease (Benoist and
Mathis 2001).
Alleles associated with MS have been identified over the last two decades, but their
explanatory power is partial at best. For example, a strong association of alleles of the
major histocompatibility complex, such as
HLA DRB1*1501, with the disease has not
been confirmed for all MS patients (Yamasaki et al. 1996; Schreiber et al. 2002). Each
time a genetic risk factor has shown a significant increase in MS risk in one population,
it has been found to be unimportant in another. This has been the case for Vitamin
D-binding protein gene polymorphisms, immune system-related polymorphisms such as
CCR5-⌬32, and the HLA DRB1*1501 allele
(Yamasaki et al. 1996; Niino et al. 2002;
Schreiber et al. 2002; Arababadi et al. 2010;
Weiner 2009; Sombekke et al. 2010).
The search for MS triggers in the context
of the autoimmunity hypothesis has not yet
led to unifying conclusions about the etiology of the disease. It also lacks a compelling
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explanation as to why women are more at
risk of developing MS than men, even
though sex has been shown to affect both
MS prevalence and the course of the disease
(Greer and McCombe 2011). In short, the
immunological framework, or autoimmune
hypothesis, clarifies neither the etiology nor
the relationship between environmental factors and the pathology of the disease.
I propose a new framework for understanding MS. Rather than a disease of the
immune system, MS is a dysfunction of the
metabolism of lipids, with mechanisms that
parallel atherosclerosis, but also differ from
that disease. Understanding MS as a chronic
metabolic disorder illuminates four aspects
of disease onset and progression: 1) its pathophysiology; 2) genetic susceptibility; 3) environmental and pathogen triggers; and 4)
the skewed sex ratio of patients. It offers a
unifying theoretical framework that excludes
none of the well-demonstrated markers and
risk factors of MS, and suggests new avenues
for treatment.
This review relates the best understood
genetic and environmental MS risk factors to
the observed pathophysiology of the disease
in the framework of a dysregulation of lipid
homeostasis. To accomplish this goal, an
overview of lipid metabolism is provided,
along with a systematic evaluation of the
links between MS risk factors and lipid metabolism. I conclude with a discussion of the
predictions emerging from applying the new
framework.
Overview of Lipid Metabolism
major pathways
There are three main pathways in the metabolism of lipids: exogenous; endogenous;
and reverse cholesterol pathway. The exogenous pathway involves the synthesis of
chylomicrons in the enterocytes of the
small intestine, where dietary lipids are absorbed after digestion by bile salts and pancreatic lipase in the pancreas. The synthesis
of chylomicrons involves the assembly of triacylglycerol (TG), cholesterol esters (CE),
and the apolipoprotein B-48 by the lipid
binding and transfer heterodimer, microsomal triglyceride transfer protein (MTP).
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Figure 1. Lipid Metabolism in Relation to the Central Nervous System
A: exogenous lipid metabolism (chylomicrons); B: endogenous lipid metabolism (VLDL and HDL synthesis); C: cholesterol efflux from peripheral macrophages by HDL (microglia). Abbreviations: A: Triacylglycerol
(TG); cholesterol esters (CE); apolipoprotein B-48 (APO48); microsomal triglyceride-transfer protein (MTP);
apolipoprotein E (Apo E); apolipoprotein CII (Apo CII); high-density lipoprotein (HDL); lipoprotein lipase
(LPL); free fatty acids (FFA); Apo E receptor (ApoE-R). B: very low-density lipoprotein (VLDL); apolipoprotein
B-100 (Apo B-100); intermediate dense lipoprotein (IDL); oxidized LDL (oxLDL); hepatic lipase (HTGL);
scavenger receptor B1 (SR-B1); cluster of differentiation 36 (CD36). C: ATP-binding cassette A1 receptor
(ABCA1); cholesterol-ester transport protein (CETP); paraoxonase-1 (PON1).

After assembly, the chylomicrons leave the
enterocytes and enter the lymphatic system,
where they emulsify and acquire two major
proteins, apolipoprotein E (Apo E) and apolipoprotein CII (Apo CII), from the highdensity lipoprotein (HDL) as they enter the
blood. The newly acquired Apo CII activates
the lipoprotein lipase (LPL) on the endothelial walls, which cleaves the triacylglycerols.
Free fatty acids (FFA) cleaved from the triacylglycerols are then mostly stored in adipose tissues, or go to the muscles for energy
production. After LPL cleavage, the liver absorbs the chylomicron remnants via the Apo
E receptor, and hepatic cells then degrade

and reuse the remnants into the endogenous lipid metabolism (Figure 1A).
The endogenous pathway involves the synthesis of very low-density lipoprotein (VLDL)
in the liver from free cholesterol esters and
free fatty acids (FFA) acquired through the
metabolism of dietary lipids. As with chylomicron synthesis, the MTP assembles VLDLs
by combining triacylglycerol (TG), cholesterol esters (CE), and the apolipoprotein
Apo B-100 (Sundaram and Yao 2010). Aside
from Apo B-100, the VLDL molecule acquires four other apolipoproteins—Apo AI,
Apo AII, Apo CII, and Apo E—all of which
affect the downstream breakdown of VLDL.
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Once formed, the TG-rich VLDL molecules
leave the liver to the serum and are processed
by the lipoprotein lipase (LPL), which breaks
down the VLDL into intermediate dense lipoprotein (IDL) and oxidized LDL (oxLDL).
The LPL is then activated by the Apo CII protein, and ligates the VLDL into FFAs that go
to either the production of energy or to storage cells (adipocytes). IDL breaks down into
LDL molecules through the removal of TG
by the hepatic lipase (HTGL). The liver absorbs most LDL molecules through binding
with the scavenger receptor B1 (SR-B1). Peripheral cells and endothelial macrophages
also absorb some LDL molecules via scavenger receptors, SR-B1 and CD36. The cholesterol contained in LDL is then used for the
synthesis of membranes and steroids. Endothelial macrophages uptake excess LDL and
CE molecules in the plasma. Lipid-laden
macrophages either go through an autoregulated apoptotic mechanism, or are emptied out of their lipid content by the reverse
cholesterol pathway (Figure 1B).
In the reverse cholesterol pathway, the
HDL molecule binds to the ATP-binding cassette A1 (ABCA1) receptor and removes the
excess free cholesterol esters from the macrophages via the HDL cholesterol ester transport protein (CETP). The cholesterol esters
are transported to the liver, where they are
reused for the synthesis of VLDLs or catabolized (Figure 1C).
peroxisomes, fatty acid oxidation,
and the peroxisome
proliferator-activated receptors
(ppars): central nodes of lipid
metabolism
At the center of lipid metabolism are the
peroxisomes, specialized organelles abundant in the liver cells. The peroxisomes regulate lipid metabolism by: a) by breaking
down the long chain of fatty acids before
they can be used by the mitochondria for
energy production; b) by breaking down the
free radical hydrogen peroxide; c) by downregulating the LPL inhibitor Apo CIII, increasing VLDL and chylomicron lipase; d)
by synthesizing cholesterol through synthesis
of HMG-CoA reductase; and e) by increasing
synthesis of bile acids that catabolize triacyl-
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glycerols. The peroxisomes work in tandem
with the mitochondria as primary site of
␤-oxidation of very long chain (VCLFAs) and
branched chain fatty acids (BCFAs), which
are essential for the synthesis of myelin
(Hulshagen et al. 2008; Baes and Aubourg
2009; Chrast et al. 2011). These fatty acids,
too long to be processed by the mitochondria, are transported into the peroxisome by
the ABCD1 transporter and are activated by
the acyl-CoA synthesase (ACS) in the outer
membrane of the peroxisome. Branched
chains of fatty acids, such as dietary phytanic
acid, first go through ␣-oxidation, where
they are broken down to pristanic acid. Both
pristanic acid and the newly formed acyl-CoA
derivatives go through ␤-oxidation and are catalyzed by hydrogen peroxide (H2O2) first, then
by enoyl-CoA hydratase, hydroxyacyl-CoA dehydrogenase, and thiolase. The ␤-oxidation
continues until short and medium chains of
acyl-CoA are produced. Acetylcarnitine transferase converts the short and medium chains
of acyl-CoA into carnitine derivatives,
which are then transferred to the mitochondrion via the carnitine palmitoyltransferase I (CPT I) located in the outer
membrane of the organelle. Carnitine
palmitoyltransferase II (CPT II), located on
the inner membrane of the mitochondrion,
converts the short and medium chain carnitine derivatives back to acyl-CoA to be further catalyzed by ␤-oxidation. Unlike the
␤-oxidation of the peroxisomes, the mitochondrial ␤-oxidation produces energy
(ATP) through the reoxidation of the dehydrogenase products NADH and FAD(2H).
NAD⫹ and FAD are produced by the oxidation of the ␤-carbon chain of the fatty acylCoA to a keto group. The first enzyme of
mitochondrial ␤-oxidation, acyl-CoA dehydrogenase, transfers electrons from the formation of a double bond between the ␤ and
␣ carbons of the fatty acyl-CoA to the electron transport chain to form FAD(2H). The
second step in ␤-oxidation is the addition of
an OH group to the ␤-carbon chain by enoyl
hydratase. The ␤-hydroxy acyl-CoA dehydrogenase then transfers electrons from oxidation of the hydroxyl group to NAD⫹ to form
NADH. Both FAD(2H) and NADH are then
reoxidized into the ␤-oxidation cycle by the
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Figure 2. Peroxisomal and Mitochondrial Oxidation of Lipids
The boxes highlight the PPAR-regulated enzymes. The abbreviations are: very long chain of fatty acids
(VLCFA); branched chain of fatty acids (BCFA); ATP-binding cassette transporter (ABC transporter); acyl-coA
oxidase (ACO); enoyl-CoA hydratase 3-hydroxyacyl-CoA dehydrogenase (HD); acyl-CoA synthetase (ACS); the
carnitine palmitoyl transferase I and II (CPTI and CPTII); carnitine-acylcarnitine translocase (CACT); acetylCoA carboxylase (ACC); fatty acid synthase (FAS).

electron chain transport, thus generating
energy (ATP). Levels of NADH and ATP
partially regulate ␤-oxidation in the mitochondria, since fatty acid oxidation cannot
happen before reoxidation of NADH and
FAD(2H). In the final step of ␤-oxidation, a
thiolase cleaves the bond between the ␤ and
␣ carbons. A CoASH is attached to the ␤
carbon, forming a shorter acyl-CoA. The reaction is repeated until all of the carbons of
the fatty acids are converted in acyl-CoA,
which can be released in the cytosol for the
production of new fatty acids (see Figure 2)
(Shi and Burn 2004).
The function and number of peroxisomes
per cell, and many of the enzymes involved in lipid and glucose metabolism
and homeostasis, are regulated by the
peroxisome proliferator-activated receptors (PPARs), nuclear receptor proteins
that function as transcription factors.
The PPAR target genes regulate the expression of enzymes involved in mitochondrial and peroxisomal FA oxidation,

microsomal FA cytochrome P450- oxidation, fatty acid transports, apolipoprotein synthesis, lipogenesis and lipolysis,
as well as glucose transport and utilization (see Tables 1, 2, and 3) (Braissant et
al. 1996). There are three subtypes of PPAR:
PPAR␣ (also known as the nuclear receptor
subfamily 1, group C, member 1—NR1C1);
PPAR␤/␦ (NR1C2), and PPAR␥ (NR1C3)
(Varga et al. 2011). To be fully functional, all
three PPARs form a heterodimer with the retinoid X receptor (RXR). PPARs are coded in
different regions of the genome (PPAR␣ on
chromosome 22, PPAR␤/␦ on chromosome
6, and PPAR␥ on chromosome 3). Although
PPARs are expressed in essentially all tissue
and cell types, they have higher expression in
specific tissues: PPAR␣ is primarily expressed
in the liver, heart, skeletal muscles, and kidney (see functions in Table 1); PPAR␤/␦ is
expressed mostly in the small intestines, colon, heart, adipose tissue, skin, and the brain
(see functions in Table 2); and the highest
levels of PPAR␥ are found in macrophages,
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TABLE 1

Regulatory functions of PPAR␣
PPAR␣
Gene

Protein/Enzyme

Effects

Lipid metabolism - Extracellular
1
Apo AI
Apolipoprotein Alpha 1
1
Apo AII
Apolipoprotein Alpha 2

Stimulates HDL synthesis

1

Apo E

Apolipoprotein Epsilon

12
12
12
1

LPL
Apo CII
Apo CIII
LCAT

Lipoprotein Lipase
Apolipoprotein CII
Apolipoprotein CIII
Lecithin:cholesterol
acyltransferase

1

CETP

Cholesteryl ester transfer
protein

Stimulates the formation of chylomicrons,
binding of lipoproteins to the liver for
catabolism and redirects endotoxin
from macrophages to hepatocytes
Regulates lipolysis (Up in fasting,
exercising and inflammatory states;
down in postpandrial states)
Stimulates transformation of cholesterol
and phosphatidylcholines to CE on
HDL surface
Stimulates uptake of CE by hepatocytes
and transfer of CE from HDL to other
lipoproteins

Lipid Metabolism - Intracellular - peroxisomes/mitochondrion
1
FATP
Fatty Acid transporter
Increases the uptake of long chain FA
protein

1

ACO

Acyl-CoA oxidase

Stimulates first step in FA ␤-oxidation

1

HD

Stimulates second and third step in FA
␤-oxidation

1

ACS

Enoyl-CoA hydratase-3hydroxyacyl-CoA
dehydrogenase
Acyl-CoA synthetase

12

CPTI

12

CPTII

12

CACT

12

MTP

Carnitine
palmitoyltransferase I
Carnitine
palmitoyltransferase II
carnitine-acylcarnitine
translocase
Microsomal triglyceride
transfer protein

Stimulates the conversion of FA into acylCoA derivatives

Regulates the transfer of long-chain FA
from the cytosol to the mitochondrial
(Up during fasting and inflammatory
state; down during postpandrial state)

Regulates the formation of chylomicrons

References
Kota et al. 2005; Rai et al.
2008; Sladkova et al.
2011
Fruchart 2001; Barbier
2002; Kota et al. 2005;
Brown and Plutzky
2007; Rai et al. 2008
Peters et al. 2003;
Bighetti et al. 2009;
Ruby et al. 2010
Barbier 2002;
Khovidhunkit et al.
2004; Fruchart 2007;
Bighetti et al. 2009
Fruchart 2001; Barbier
2002; Khovidhunkit et
al. 2004; Bighetti et al.
2009; Sundaram and
Yao 2010

Barbier 2002;
Khovidhunkit et al.
2004; Kota et al. 2005;
Ehrenborg and Krook
2009
Kota et al. 2005; Schrader
and Fahimi 2008; Baes
and Aubourg 2009;
Cheng et al. 2010;
Wagner and Wagner
2010
Kota et al. 2005; Varga et
al. 2011
Peters et al. 2000; Barbier
2002; Dressel et al.
2003; Khovidhunkit et
al. 2004; Brown and
Plutzky 2007
Khovidhunkit et al. 2004;
Davidson 2006; Wagner
and Wagner 2010

Stefano et al. 2007
continued
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TABLE 1
Continued
PPAR␣
Gene
2

Protein/Enzyme
SREBP

Sterol Regulatory ElementBinding Protein

Effects
Decreases de novo lipogenesis

Lipid metabolism - Adipocytes - Tissue specific - Energy production
1
UCP
Thermogenin
Stimulate energy production
Inflammation - Pathways
Nuclear factor kappa-light2
NF-B
Decreases transcription of inflammatory
chain-enhancer of
enzymes
activated B cells
Inflammation - Cytokines - Chemokines
1
IL-4
Interleukin-4
2
2

IL-12
COX-1

Interleukin-12
Cyclooxygenase 1

2

COX-2

Cyclooxygenase 2

Stimulates the differentiation of naive
helper T cells into Th2 (CD4⫹) cells
Decreases inflammation and eicosanoid
synthesis

Endothelium - Vasculature - Tissue specific regulatory functions
2
VAP-1
Vascular adhesion protein - 1 Decrease recruitment of T cells and
rolling monocytes

adipose tissue, colon, heart, muscle, kidney,
pancreas, and spleen (see functions in Table
3) (Brown and Plutzky 2007). Thus, the
PPARs are highly expressed in tissues heavily
dependent on lipids both for energy and
maintenance. For example, in the CNS, glial
cells use more lipids than any other tissue in
the body. Glial cells, in particular oligodendrocytes, rely heavily on peroxisomal and mitochondrial oxidation of VLCFAs, both for
fuel and structural maintenance, such as myelin synthesis (Braissant et al. 1996).
Each PPAR regulates genes by binding the
PPAR/RXR heterodimer to a promoter region known as peroxisome proliferator response element, or PPRE, of a gene. PPARs
are also activated by extracellular stimuli:
PPAR␣ is activated during starvation and cold
acclimatization, PPAR␥ is activated in well-fed
states, and the activation of PPAR␤/␦ is linked
to the consumption of energy, thermogenesis,
and CNS maintenance (Varga et al. 2011).
The transcriptional function of the PPARs
is also induced by a series of ligands, which
act as activators of PPAR binding to the
PPRE, increasing the expression of target
genes. Polyunsaturated fatty acids, such as

References
Yoshikawa et al. 2003

Handschin 2010
Khovidhunkit et al. 2004;
Duan et al. 2008; Varga
et al. 2011

Yang and Frucht 2001;
Kota et al. 2005;
Collino et al. 2006;
Fruchart 2007

Calkin et al. 2006; Cheng
et al. 2010; Varga et al.
2011

linoleic and arachidonic acids, as well as prostaglandin-related compounds, such as 15deoxy-⌬12,14-prostaglandin (15d-PGJ2), are
known to be powerful endogenous ligands to
the PPARs (Kota et al. 2005).
PPARs are nodal points among the immune system, the transcriptional regulation
of energy, and lipid homeostasis because
they sense intracellular lipid levels and modify lipid metabolism under specific conditions in both major organs and peripheral
cells (see Figure 3) (Evans et al. 2004;
Khovidhunkit et al. 2004; Brown and Plutzky
2007; Varga et al. 2011). As such, they play a
major role in the etiology of MS, as described
in detail below.
Pathophysiology of MS: Links to
Lipid Homeostasis and
Atherosclerosis
The pathways to inflammation and plaque
formation in MS and atherosclerosis parallel
each other. Lipid dysregulation through either diet or endogenous mechanisms is
clearly linked to atherosclerosis, but MS is
construed as an immune system dysfunction.
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TABLE 2

Regulatory functions of PPAR ␤/␦
PPAR␤/␦
Genes

Protein/enzyme

Lipid metabolism - Extracellular
1
PON1
Paraoxonase 1

12

Apo B

Apolipoprotein B

Effects
Stimulates the prevention
of oxidation of LDL by
HDL
Regulates the formation of
chylomicrons and VLDLs
(Up during fasting state,
down during
postpandrial state)

Lipid Metabolism - Intracellular - peroxisomes/mitochondrion
12
ACS2
Acyl-CoA synthetase-2
Regulates the conversion of
FA into acyl-CoA
derivatives, affecting
postranslational
modification of myelin
synthesis
12
CPTI
Carnitine
Regulates the transfer of
palmitoyltransferase I
long-chain FA from the
cytosol to the
12
CPTII
Carnitine
mitochondrial (Up
palmitoyltransferase II
during fasting and
12
CACT
carnitine-acylcarnitine
inflammatory state; down
translocase
during postpandrial
state)
1
MCAD
Medium-chain acyl-CoA
Stimulates the first step in
␤-oxidation of mediumdehydrogenase
chain FA
1
ME
Malic enzyme
Stimulates malate
decarboxylation,
providing NADPH for
FA synthesis
1
PEPCK
Phosphoenolpyruvate
Stimulates gluconeogenesis
carboxykinase
and glyceroneogenesis
2

ACC

acetyl-CoA carboxylase

2

FAS

Fatty acid synthase

2

SREBP

Sterol Regulatory
Element-Binding
Protein

Decreases acetyl-CoA
carboylase
Decreases FA synthesis
Decreases de novo
lipogenesis

Lipid metabolism - Adipocytes - Tissue specific - Energy production
1
FABP
Fatty acid-binding protein
Stimulates adipocyte
differentiation and
binding of FA

References
Khovidhunkit et al. 2004;
Brown and Plutzky 2007;
Marsillach et al. 2009
Bishop-Bailey and Bystrom
2009

Hall et al. 2008

Dressel et al. 2003;
Khovidhunkit et al. 2004;
Wagner and Wagner 2010

Wagner and Wagner 2010

Bishop-Bailey and Bystrom
2009; Varga et al. 2011

Moller and Berger 2003;
Ehrenborg and Krook
2009
Khovidhunkit et al. 2004;
Lunde et al. 2007
Barbier 2002; Dressel et al.
2003
Dressel et al. 2003;
Ehrenborg and Krook
2009

Bocher et al. 2002; Dressel
et al. 2003; Sprecher et al.
2007; Ehrenborg and
Krook 2009; Wagner and
Wagner 2010
continued
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TABLE 2
Continued
PPAR␤/␦
Genes

Protein/enzyme

1

C/EBP

1

UCP

1
1

GLUT4
TXNIP

Inflammation - Pathways
2
NF-kB

2

MAPK/ERK

1

BCL-6

CCAAT/enhancer-binding
protein
Thermogenin
Glucose transporter type 4
Thioredoxin-binding
protein-2

Nuclear factor kappa-lightchain-enhancer of
activated B cells
pathway
Mitogen-activated protein
(MAP) kinases/
extracellular-signalregulated kinases
pathway
B-cell lymphoma 6 protein

Inflammation - Cytokines - Chemokines - ROS
Interferon gamma
2
IFN-␥
Tumor necrosis factor2
TN␣
alpha
Interleukin-1 beta
2
IL-1␤
2
IL-6
Interleukin-6
2
Isg20
Interferon-stimulated gene
20 kDa protein
2
GM-CSF
2
MCP-1/CCL2
Monocyte-specific
chemokine 2/
Chemokine (C-C motif)
ligand 2
2
MCP-3/CCL7
Monocyte-specific
chemokine 3/
Chemokine (C-C motif)
ligand 7 (CCL7)
2
MCP-5/CCL12
Monocyte-specific
chemokine 5/
Chemokine (C-C motif)
ligand 12 (CCL12)
2
CXCL7
Chemokine (C-X-C motif)
ligand 7
2
CCL21
Chemokine (C-C motif)
ligand 21
2
CCR2
Chemokine receptor 2

Effects

Stimulate energy
production
Stimulates glucose transport

References
Bocher et al. 2002; Takata et
al. 2002; Glazer et al. 2008
Dressel et al. 2003; Wagner
and Wagner 2010

Khovidhunkit et al. 2004;
Varga et al. 2011

Decreases transcription of
inflammatory enzymes

Wagner and Wagner 2010;
D’Angelo et al. 2011

Increases the modulation
of the transcription of
STAT-dependent
interleukin responses of
B cells

Barish et al. 2008; Glazer et
al. 2008; Hall et al. 2008;
Bishop-Bailey and
Bystrom 2009; Wagner
and Wagner 2010;
D’Angelo et al. 2011

Decreases the transcription
of inflammatory
enzymes, oxidants and
chemoattractant ligands
and decreases the
stimulation of platelet
activation, cell
proliferation,
extracellular matrix
synthesis, and glucose
metabolism

Barish et al. 2008; BishopBailey and Bystrom 2009;
Wagner and Wagner 2010

continued
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TABLE 2
Continued
PPAR␤/␦
Genes

Protein/enzyme

1

RGS4

1

RGS5

1

TIMP3

1

SOCS3

Suppressor of cytokine
signaling 3

1

SOD1

Superoxide dismutase

1

CAT

Catalase

1

TXN

Thioredoxin

1

YWHAA/14-3-3a

Tyrosine 3monooxygenase /
tryptophan 5monooxygenase
activation protein,
alpha polypeptide

Regulator of G protein
signaling 4
Regulator of G protein
signaling 5
Metalloproteinase
inhibitor 3

Effects
Stimulates G-protein
signaling
Increases the inhibition of
matrix metalloproteinase
inflammatory functions
Increases the inhibition of
cytokine signaling
Increases the
decomposition of
superoxide radicals
Increases the
decomposition of
hydrogen peroxide to
water and oxygen in the
peroxisomes
Increases the antioxidant
functions of this
oxidoreductase enzyme
Stimulates synthesis of the
dopamine (DOPA),
norepinephrine
(noradrenaline), and
epinephrine
(adrenaline) precursors

Endothelium - Vasculature - Tissue specific regulatory functions
2
VCAM-1
Vascular cell adhesion
Maintain the plasticity,
(CD106)
protein 1
flexibility, and
permeability of blood
2
ICAM-1 (CD54)
Inter-Cellular Adhesion
vessels and decrease
Molecule 1
adhesion of rolling
2
E-selectin
CD62 antigen-like family
monocytes and
(CD62)
member E/
agglutination of platelets
Endothelial-leukocyte
adhesion molecule 1
(ECAM-1)
Chemokine (C-X-C motif)
Decreases the migration of
2
GRO␣/CXCL1
ligand 1 (CXCL1)
oligodendrocyte
precursors, angiogenesis,
inflammation, and
tumorigenesis
1
VEGF
Vascular endothelial
Increases vasculogenesis
growth factor
and angiogenesis

References
Barish et al. 2008; BishopBailey and Bystrom 2009

Rock et al. 2004; BishopBailey and Bystrom 2009;
Wagner and Wagner 2010
Thomas et al. 2006; Qin et
al. 2007; Bishop-Bailey
and Bystrom 2009
Hou et al. 2005; BishopBailey and Bystrom 2009
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TABLE 2
Continued
PPAR␤/␦
Genes

Protein/enzyme

1

Akt

Akt-protein kinase

1

TGF␤

Transforming growth
factor beta

2

CN A␤

Calcineurin A␤

2

PGC-1␣

Peroxisome proliferatoractivated receptor
gamma coactivator 1alpha

Understanding MS in the same context as
atherosclerosis explains aspects of MS better
than the immune dysfunction model by providing a unifying physiological framework. A
rapidly increasing body of literature documents how lipids or lipid regulators produce
oxidative damage and inflammation in MS
(Witherick et al. 2010; Chrast et al. 2011;
Varga et al. 2011). The parallels between the
mechanisms described for MS and atherogenesis are striking. Although atherosclerosis
is localized to the artery walls and MS to the
central nervous system (CNS), lesions in
both diseases are essentially the same, and
parallel mechanisms underlie their formation. These mechanisms can be summarized
as: 1) dysregulation of cholesterol compound
formation; 2) differentiation of macrophages
into cytotoxic foam cells; 3) inflammatory response; and 4) accumulation of foam cells and
formation of lesions.
Where atherosclerosis and MS differ is in
the exposure of particular tissues to foam
cells, inflammation, and lesion formation
(steps 2 through 4). The CNS and the brain
are shielded by the blood brain barrier
(BBB), a specific high-density endothelial
layer that restricts the passage of solutes from
the bloodstream. The CNS has its own mac-

Effects
Induces cellular survival
pathways by inhibiting
apoptotic processes.
Induces skeletal muscle
hypertrophy, and
general tissue growth,
including angiogenesis
Induces TGF pathway that
inhibits cell
proliferation, induces
differentiation, and
promotes apoptosis
Stimulates muscle growth
and angiogenesis
Stimulates activation of
PGC-1␣ in skeletal
muscles
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2008; Bishop-Bailey and
Bystrom 2009; Wagner
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Yang and Frucht 2001;
Bishop-Bailey and
Bystrom 2009

Wagner and Wagner 2010
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rophages, the microglia, which are very similar in morphology and immunophenotype
to the macrophages of the peripheral/
perivascular tissues involved in atherogenesis. The origin of microglial cells is still debated (Kofler and Wiley 2011), but the CNS
contains a highly stable pool of microglia
formed during embryonic development. Microglia permanently monitor the integrity of
the CNS tissues in normal conditions (Wake
et al. 2009). Through a highly ramified system of receptors, they can detect the state of
cells in their neighborhood and respond
quickly to the ATP release of distressed cells,
or an excess of oxLDL (Davalos et al. 2005;
Nimmerjahn et al. 2005; Monk and Shaw
2006; Wake et al. 2009). During inflammation, bone marrow-derived rolling monocytes differentiate into microglial cells and
infiltrate the blood brain barrier in a process
similar to the formation of perivascular macrophages (Rock et al. 2004; Ladeby et al.
2005). The functions of the microglia are
similar to bone marrow-derived perivascular
macrophages in atherosclerosis, although
they differ in their location-specific potential neurotoxicity when activated
(Malchiodi-Albedi et al. 2008). Under normal circumstances, an autoregulatory mecha-
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TABLE 3

Regulatory functions of PPAR␥
PPAR␥
Gene

Protein/Enzyme

Lipid metabolism – Extracellular
1
ABCG1
ATP-binding casette G1
1
ABCA1
ATP-binding casette A1
12
12

CD36
SR-B1

Scavenger receptor
Scavenger receptor

1

Apo E

Apolipoprotein Epsilon

Effects
Stimulates reverse
cholesterol efflux
Regulates entry of FA and
lipoproteins in cells
under specific lipid
stimulation
Stimulates the formation of
chylomicrons and
binding of lipoproteins
to the liver for
catabolism

Lipid Metabolism - Intracellular - peroxisomes/mitochondrion
1
CYP4A6 (P450) Cytochrome P450 enzyme
Stimulates FA -hydrolase
1

HMG-CoAS

1

ME

1

PEPCK

2

ACC

Phosphoenolpyruvate
carboxykinase
acetyl-CoA carboxylase

2

FAS

Fatty acid synthase

Decreases FA synthesis

2

SREBP

Sterol Regulatory
Element-Binding
Protein

Decreases de novo
lipogenesis

Mitochondrial 3-hydroxy3-methylglutaryl CoA
synthase
Malic enzyme

Stimulates liver ketogenesis

Stimulates malate
decarboxylation,
providing NADPH for
FA synthesis
Stimulates gluconeogenesis
and glyceroneogenesis
Decreases acetyl-CoA
carboylase

Lipid metabolism - Adipocytes
1
FABP
Fatty acid-binding protein

1

C/EBP

1

ADPN

CCAAT/enhancer-binding
protein
Adiponectin

1

ADN

Adipsin

1
1

GLUT4
TXNIP

Glucose transporter type 4
Thioredoxin-binding
protein-2

Stimulates adipocyte
differentiation

Stimulates glucose
regulation and FA
catabolism
Stimulates synthesis of C3
convertase in the
alternative complement
pathway
Stimulates glucose
transport
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TABLE 3
Continued
PPAR␥
Gene

Protein/Enzyme

Inflammation – Pathways
Nuclear factor kappa-light2
NF-B
chain-enhancer of
activated B cells
2

STAT-1

2

AP-1

JAK-STAT signaling
pathway
Activator protein 1

Effects
Decreases transcription of
inflammatory enzymes

Decreases transcription of
inflammatory enzymes
Decreases differentiation,
proliferation, and
increases apoptosis

Inflammation - Cytokines - Chemokines
Interferon gamma
2
IFN-␥
2

MHC II

2

TN␣

2
2
2
2
2

IL-1␤
IL-6
MMP-9
MMP-6
IP-10/CXCL10

2

Mig/CXCL9

2

I-TAC/CXCL11

Major Histocompatibilty
Complex, Class II
Tumor necrosis factoralpha
Interleukin-1 beta
Interleukin-6
Matrix metallopeptidase 9
Matrix metallopeptidase 6
Interferon gammainduced protein 10
(CXCL10)
Monokine induced by
gamma interferon
(CXCL9)
Interferon-inducible T-cell
alpha chemoattractant
(CXCL11)

Decreases the transcription
of inflammatory
enzymes, oxidants, and
chemoattractant ligands
(MHC II, CXCLs)

Endothelium - Vasculature - Tissue specific regulatory functions
1
eNO
Endothelial nitric oxide
Maintains the plasticity,
flexibility, and
2
ET-1
Endothelin-1
permeability of blood
2
VCAM-1
Vascular cell adhesion
vessels and decreases
(CD106)
protein 1
adhesion and
2
ICAM-1
Inter-Cellular Adhesion
recruitment of rolling
(CD54)
Molecule 1
monocytes and
agglutination of platelets

nism prevents potential neurotoxicity by the
apoptosis of the activated microglial cells
(Lee et al. 2003). Crucial for understanding
MS pathogenesis, the gene expression of activated microglia induces molecular alterations of pathways of metabolism of lipids and
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membranes (Carson et al. 2004; Qin et al.
2007). It is precisely the infiltrating macrophages—the perivascular microglia—that
contribute the most to neurodegeneration
in MS, rather than the resident parenchymal
microglia (Carson et al. 2004). The role
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Figure 3. Regulatory Functions of the Peroxisome Proliferator Activated Receptors (PPARs)
The side arrows indicate the feedback from the regulated systems and enzymes on the functions of the
PPARs. A full list of the PPAR-regulated elements is given in Tables 1, 2, and 3.

of perivascular microglia in neurodegeneration highlights the mechanistic similarity
of atherosclerosis and multiple sclerosis.
Another line of evidence pointing to
the similarities between atherosclerosis
and multiple sclerosis is a recent development in MS treatment. Atherosclerosisspecific drugs, such as statins and, more
recently, PPARs agonists, are currently used
to treat MS symptoms (Assmann and Gotto
2004; Rubic et al. 2004; DeAngelis and Lublin 2008; Heinecke 2009; Mandosi et al.

2010; Chrast et al. 2011; Mirabelli-Badenier et
al. 2011; Rinaldi et al. 2011), highlighting the
shared pathways underlying inflammatory
events in the two diseases. Statins and PPAR
agonists taken separately can successfully treat
specific symptoms (Brown and Plutzky 2007).
The new framework for understanding MS
suggests that instead of inhibition or increase
of single targets, modulation of target expression through a careful combination of
both kinds of drugs would be more beneficial to patients. A systemic approach to treat-
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ment based on lipid metabolism feedbacks
can more readily attenuate MS degeneration
than the current approach of treating the
disease as a collection of symptoms to be
relieved (Brown and Plutzky 2007).
Inflammatory pathways are, however, not
the only shared features of atherosclerosis
and multiple sclerosis: the same disequilibrium in lipid homeostasis leads to both diseases and suggests a model mechanism for
the etiology of MS.
lipid metabolism during the
acute-phase response in ms
The similarity between the lipid profile of
MS patients and that of patients suffering from
infection or inflammation was observed early
on, although researchers could not explain the
link between the two at the time (Holman et al.
1989). The immune response to an infectious agent or trauma is costly to the host in
terms of lipid catalysis. Indeed, acute-phase
responses to infection and inflammation produce dramatic changes in lipid metabolism
by increasing: adipose tissue lipolysis; hepatic
TG and FA synthesis (by increasing levels of
HMG-CoA reductase); and hepatic cholesterol synthesis (VLDLs); and decreasing both
hepatic clearance of the VLDLs and reverse
cholesterol transport (Calder et al. 1999;
Khovidhunkit et al. 2004). This reduction in
lipid storage and increased lipolysis helps deploy lipids in the immune system, either as
anti-inflammatory agents or as building blocks
of new cells.
Changes in lipid metabolism during infection or inflammation mirror the lipid profile
of MS patients in elevated plasma cholesterol
content (Cunnane et al. 1989), elevated levels of lipid hydroperoxides (Ferretti et al.
2005), elevated levels of oleic, palmitic, and
palmitoleic acids, and low levels of Apo A1
(Sladkova et al. 2011). As in pathogenic and
trauma-related inflammation, the acute and
advanced stages of MS are characterized by
lower levels of linoleic acids in plasma cholesteryl esters (Love et al. 1974; Cunnane et
al. 1989; Marshall 1991). Some of the shared
features of inflammatory responses and MS
directly involve lipid metabolism; e.g., impaired metabolism of polyunsaturated fatty
acids, evident by reduced levels of omega-3
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fatty acids in plasma and in cell membranes
(Aupperle et al. 2008; Mehta et al. 2009);
and compensation for low levels of polyunsaturated fatty acids by endogenous synthesis
of lower-melting, short-chain, saturated, and
monounsaturated nonessential fatty acids
(Cunnane et al. 1989; Holman et al. 1989).
In short, the lipid profile of MS patients is
indicative of both inflammation and a dysregulation of the metabolism of lipids.
the ppar/rxr heterodimers: at the
crossroad between lipid and immune
system homeostasis
The PPAR/RXR heterodimers regulate key
enzymes involved in the intake, synthesis, cleavage, oxidation, and efflux of lipids, which are
also involved in the immune system acutephase response (see Tables 1, 2, and 3). The
role of these PPARs-regulated enzymes is to
accelerate lipolysis and endogenous lipogenesis so lipids can be redirected to immune cells
and repair sites. Thus, a dysregulation of lipids,
such as a rise of oxidized lipid/phospholipids
either through a high fat/carbohydrate diet
or genetic predisposition (or both), alters
the regulatory functions of these lipidsensing nuclear receptors dramatically,
leading to the breakdown of homeostasis
of both lipid metabolism and the immune
system (Kota et al. 2005; Varga et al. 2011).
The PPARs contribute to lipid homeostasis
in the three main pathways of fat metabolism:
the exogenous, endogenous, and cholesterol
efflux pathways. At the exogenous levels, the
PPARs play a critical role in regulating
the synthesis of chylomicrons, by regulating
the production of the microsomal triglyceride transfer protein (MTP) and apolipoproteins B and E (Stefano et al. 2007; Rai et al.
2008; Bishop-Bailey and Bystrom 2009).
PPAR␣ and ␤/␦ also regulate lipolysis
through regulation of the synthesis of apolipoprotein CII (Peters et al. 2003). PPARs
also play a vital role in the intake and digestion of carbohydrates by regulating glucose
transport and glycogen synthesis through the
glucose transporter type 4 (GLUT4) and thioredoxin-binding protein (TXNIP), and
glucogenesis through the phosphoenolpyruvate carboxykinase (PEPCK), adiponectin (ADPN), and adipsin (AND) (Auwerx et
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al. 1996; Schoonjans et al. 1996; Moller and
Berger 2003; Hammarstedt et al. 2005;
Sharma and Staels 2007; Stefano et al. 2007;
Cho et al. 2008; Wagner and Wagner 2010).
PPARs are also responsible for the regulation
of both morphology and functions of adipocytes, by upregulating lipolysis during a
fasting state or inflammatory state, and downregulating lipolysis and stimulating TG storage
during the postprandial state (PPAR␥), as well
as by stimulating adipocyte differentiation and
binding of FA through regulation of the fatty
acid-binding protein (FABP) (Bocher et al.
2002; Sharma and Staels 2007).
In the endogenous pathways, PPARs regulate key enzymes involved in the intake,
oxidation, and de novo synthesis of fatty acids (Schoonjans et al. 1996; Moller and Berger 2003; Evans et al. 2004; Roberts et al.
2004; Shi and Burn 2004; Sundaram and Yao
2010). PPARs regulate the intake and activation of fatty acids in cells (more markedly in
hepatocytes), through regulation of: a) the
fatty acid transporter protein (FATP) for entry into cells; b) acyl-CoA synthetase (ACS)
for activation of fatty acids prior to ␤-oxidation; c) the carnitine palmitoyltransferase I
and II (CPTI and CPTII) for transports
of fatty acid carnitine derivatives into the mitochondria; d) carnitine-acylcarnitine translocase (CACT) for reactivation of carnitine
derivatives into acyl-CoAs; and e) acetyl-CoA
carboxylase (ACC), which regulates the synthesis of malonyl-CoA, a known regulator of the
CPT functions (Schoonjans et al. 1996; Herzig
et al. 2003; Sharma and Staels 2007; Shi and
Burn 2004; Stefano et al. 2007; Lim et al.
2010). The ␤-oxidation of lipids, both in the
peroxisomes and the mitochondria is, in great
part, controlled by regulation of key enzymes
in the reaction by PPARs (Figure 2). The
PPARs control the expression of: a) acyl-CoA
oxidase (ACO), the first enzyme of ␤-oxidation
in the peroxisome; b) enoyl-CoA hydratase/
3-hydroxyacyl-CoA dehydrogenase (HD), the
third and second step of ␤-oxidation in the
peroxisome; and c) the medium-chain acylCoA dehydrogenase (MACD), which oxidize
medium chain fatty acids into medium acetylCoA in the mitochondria (Schoonjans et al.
1996). PPARs also control many of the enzymes active in lipogenesis and in ketogene-
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sis, such as the fatty acid synthase (FAS), the
malic enzyme (ME), the sterol regulatory element binding protein (SREBP)—all three
leading to de novo fatty acid synthesis, and
the HMG-CoA synthase (HMG-CoAS) leading to ketone bodies synthesis (Peters et al.
2003; Khovidhunkit et al. 2004; Sharma and
Staels 2007; Cho et al. 2008; Chrast et al.
2011).
The PPARs also play a crucial role in the
cholesterol efflux from peripheral macrophages. PPARs regulate the synthesis and
function of cholesterol molecules, which intake excess oxLDL from lipid-laden macrophages. Faulty PPAR regulation caused by
environmental triggers and/or genetic predisposition disable lipid homeostasis through the
dysregulation of the three pathways of lipid
metabolism, in turn leading to a toxic accumulation of oxLDL, both in plasma and in
peripheral macrophages (Figure 4). This triggers responses that further compromise lipid
metabolism, resulting in a feedback loop.
The dysregulated PPARs accelerate monocyte
differentiation into toxic macrophages/
microglial cells (Yu and Cooper 2001; Malchiodi-Albedi et al. 2008) and compromise
the integrity of the blood brain barrier (Airas
et al. 2006). OxLDLs can now more freely
cross into the endothelial layers where an
increased amount of CNS macrophages (microglia) absorb them in excess through the
overexpression of the PPARs-regulated SRB1/CD36 scavenger receptors. This leads to
the differentiation of cytotoxic microglia
into foam cells. The accumulation of foam
cells causes oxidative damage, and the antiinflammatory responses to excess oxLDL,
usually mediated by the PPARs, fails to prevent both the expression of interleukin 6
(IL-6), NF-B, and C/EBP, and the synthesis
of free radicals (Khovidhunkit et al. 2004;
Witherick et al. 2010; Haider et al. 2011).
The apoptosis of the now highly cytotoxic microglial foam cells, also regulated by the
PPAR/RXR heterodimers (Harris and Phipps
2001; Yang and Frucht 2001; Qin et al. 2007;
Glazer et al. 2008), no longer occurs, generating more inflammation, and the fatty
streaks plaques observed in MS lesions (Paumen et al. 1997; Boullier et al. 2001). The
oxidative injuries and accumulation of
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Figure 4. Loop Mechanism of the Etiology of MS

foam cells lead to demyelination through
the oxidation of myelin phospholipids by
circulating free radicals, and indiscriminate
phospholipid endocytosis by the cytotoxic microglial and T cells.
The dysregulation of the immune system,
which relies entirely on lipids for repair and
to prevent/stave off inflammation, follows
from the disequilibrium in lipid metabolism
(and not the other way around). I propose
that the mechanism of pathogenesis of MS
originates in a dysregulation of lipid homeostasis, due to the dual action of faulty PPAR
genes (or specific faulty alleles regulated or

linked to the PPARs) and environmental
triggers, such as diet and pathogens, accentuating this dysregulation in a loop.
the role of lipid metabolism and the
nuclear receptors in the intake of
oxidized lipids by dysfunctional
microglial cells: the
pathogen-trigger theory of ms
etiology
Lipids, and specifically oxLDLs, are the core
agents of the immune system during the acutephase response to infection/inflammation
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(Khovidhunkit et al. 2004). The oxLDLs bind
to the lipopolysaccharide (LPS) membrane of
the infectious agent (bacteria, virus, or parasite), allowing endocytosis by the macrophages
via the scavenger receptors (SR-B1, CD36,
ABCA1). In the nonacute phase, all three major receptors, regulated by the PPAR/RXR heterodimers, work toward removing excessive
amounts of TG from the plasma. This action
regulates the endogenous lipid metabolism, including cholesterol efflux by HDL.
All scavenger receptors have a high affinity
for cholesterol and oxidized phospholipids,
a property that explains their involvement
in immune system response to pathogens
(Janabi et al. 2000; Van Eck et al. 2004;
Svensson et al. 2005; Vergeer et al. 2011).
Binding to the damaged, oxidized, infected
macrophages initiates phagocytosis in a process similar to that of removal of foam cells
from the endothelial layers of blood vessels.
But an overexpression of the two main scavenger receptors, SR-B1 and CD36, is deleterious.
PPAR␥-regulated CD36 overexpression in microglia increases free radicals, increasing the
levels of oxLDLs, turning on the overexpression of the receptors in a feedback loop (Cho
et al. 2005).
In MS, CD36 overexpression is associated
with both acute relapsing episodes (Ferrandi
et al. 2011) and ischemic brain (Cho et al.
2005), linking this scavenger receptor to
CNS damage. Under hyperlipidemic conditions, platelet-expressed CD36 sense oxidative stress and modulate platelet reactivity,
leading to vascular atrophy and thrombosis
(Podrez et al. 2000). By increasing platelet
aggregation, CD36 alters the structure and
permeability of the BBB, increasing the adherence of platelets to microvascular beds
and activating the neurotoxic cytokines (Coltel et al. 2006). This inflammatory mechanism of CD36 has been well described in the
context of parasitic and microbial infections
(Febbraio and Hajjar 2001; Huang and Jong
2001; Combes et al. 2006). MS patients have
significantly higher platelet activity (Sheremata et al. 2008), suggesting this mechanism
is implicated in the pathogenesis of MS.
The expression of SR-B1, mediated by
PPAR/RXR heterodimers, also increases the
intake of free fatty acids by the endothelial
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macrophages. SR-B1 expression appears to
be beneficial in atherosclerosis (Ahmed et al.
2009) and polymorphisms in the PPAR/RXRregulated SR-B1 coding gene, SCARB1, decrease insulin-resistance and lower oxLDL in
plasma in populations with a high polyunsaturated diet (Pérez-Martı́nez et al. 2005).
But overexpression of the SR-B1 receptor
induces peripheral cells into nonspecific
excess intake of fatty acids (Trigatti et al.
2003; Van Eck et al. 2004).
The affinity of CD36 and the closely linked
SR-B1 to a variety of pathogens, including
mycobacteria and hepatitis viruses, also explains why so many pathogenic triggers for
MS have been uncovered (Philips et al. 2005;
Cunha-Rodrigues et al. 2007; Barth et al.
2008; Catanese et al. 2010; Hawkes et al.
2010). The binding affinity of scavenger receptors can explain the overrepresentation
of specific pathogens, such as EBV, in MS
lesions (Febbraio and Hajjar 2001; CunhaRodrigues et al. 2007; Barth et al. 2008; Catanese et al. 2010; Hawkes et al. 2010). But
the autoimmunity theory of MS pathogenesis has so far failed to account for the lack of
specificity of pathogenic triggers. In the context of a runaway feedback involving scavenger receptors and oxidized LDL, it is not the
specific pathogens that precipitate MS etiology, but the affinity of immune cells to respond to damaged, oxidized cells that mimic
the structure of infected cells or cell membranes of microbial and parasitic pathogens
(Blewett 2010).
The proposed etiology of MS is either an
increase of oxidized phospholipids through
genetically faulty PPARs, combined with a
diet high in triglycerides that lead to a dysregulation of the scavenger receptors and
lipid homeostasis. A pathogen trigger exacerbates the imbalance of lipid homeostasis
by shifting the lipid metabolism from energy
production and lipid storage to the production of more TG by lipolysis and lipogenesis,
leading to a greater number and intake of oxLDLs by peripheral macrophages. In pathogen-triggered MS, overexpression of CD36 and
SR-B1 leads to nonspecific, indiscriminate
binding to phospholipids via oxLDL, at first
pathogenic in origin, but then turning to the
native phospholipid-rich myelin. This hypo-
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thetical mechanism is not exclusive to a specific pathogen as trigger of the inflammatory
vicious circle observed in MS.
the role of lipid metabolism and the
nuclear receptors in the
dysregulation of hdl cholesterol
efflux and composition of the hdl
membrane: the diet-trigger theory of
ms etiology
The overexpression of the CD36 and
SR-B1 scavenger receptors is further exacerbated by a lack of cholesterol efflux from the
macrophages. Downregulation of the Apo
A1 gene, regulated by PPAR␣, explains the
low levels of apolipoprotein A1 (Apo A1)
observed in MS patients (Burger and Dayer
2002; Sundaram and Yao 2010; Sladkova et
al. 2011). A downregulation of the ABCA1
receptor and a lower level of Apo A1 in the
liver and serum contribute to a saturation of
macrophages with cholesteryl esters and long
fatty acids. The downregulation of Apo A1 synthesis also reduces the anti-inflammatory
functions of the protein (Burger and Dayer
2002), the formation of nascent HDL molecules in plasma, and impairs the functions of
the ABCA1 receptors, which in turn impairs
the reverse cholesterol process.
The reverse cholesterol pathway is further impaired by a shift of HDL composition. In a diet high in polyunsaturated
fatty acids (PUFAs), and low in triglycerides, the PPAR␣-regulated HDL phospholipids have a polyunsaturated linoleic
acid (PLPC) in the ␤ position (Fruchart
2001, 2007). These PLPC-HDL inhibit the
proliferation of proinflammatory LPS by
binding to them and the acute phase serum
amyloid A (SAA), as well as by decreasing the
expression of adhesion molecule (VAP-1) in
peripheral endothelial cells (Baumberger et
al. 1991; Baker et al. 2000). HLD with high
PLPC content is also a potent antioxidant,
preventing the oxidation of LDL molecules
into oxLDL (Brodeur et al. 2008). Conversely, a high triglyceride diet leads to the
composition of HDL with monounsaturated
oleic acid (POPC) or polyunsaturated arachidonic acid (PAPC) in the ␤ position.
POPC or PAPC-HDL has none or little of the
functions of HDL described above. The an-
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tioxidant properties of HDL are further inhibited by a decrease in serum levels of the
paraoxonase-1 (PON1), an enzyme regulated by PPAR␦ that hydrolyzes lipid peroxides, bound to HDL (Marsillach et al. 2009).
A deficiency in the regulatory expression of
PPAR␦ decreases PON1 expression, decreasing HDL synthesis, and depressing the LDL
antioxidant function of HDL. All of these
changes lead to more oxLDLs in both
plasma and macrophages (Ferretti et al.
2005). All of the PPAR-mediated lipid metabolism dysfunctions— high oleic acid, high
oxLDL, high SAA expression, high VAP-1
expression, low PON1, and low PUFA—
characterize the observed lipid and enzymatic
profile of MS patients (Jamroz-Wisniewska et
al. 2009).
The low levels of PUFAs in MS patients are
consistent with the dietary/lipid homeostatic
origin of the disease and directly relate to the
function of PPARs. The new framework explains why treating MS patients with a diet
high in omega-3 fatty acids has been an effective way of lowering demyelination and
inflammation (Cunnane et al. 1989; Zhang
et al. 2000; Besler et al. 2002; Habek et al.
2010). PUFAs are known activators of the
PPARs, which in turn regulate the lipogenesiscontrolling sterol receptor element binding
protein–1c (SREBP-1c) (Yoshikawa et al.
2003). Reduced expression of SREBP-1c leads
to the upregulation of fatty acid oxidation in
hepatocytes, and enhances the catabolism of
glucose to glycogens through downregulation
of nuclear factor HNF4␣ (Davidson 2006).
The oxidation of fatty acids in both adipocytes
and plasma decreases VLDL synthesis. In a fasting state and under severe inflammation, the
cAMP response element-binding (CREB)
downregulates hepatic PPAR␥ expression,
thus activating gluconeogenic and fatty acid
oxidation by stimulating expression of the
nuclear hormone receptor coactivator
PGC-1 (Herzig et al. 2003; Sue et al. 2009).
Modulation in the expression of the PPAR␣
and ␥ leads to the opposite effect: lower FA
oxidation in the peroxisome, higher FA oxidation in the mitochondria, and the release
of SREBP-1 and de novo lipogenesis. This
lipid profile results in high nonoxidized
VLCFAs in cells and serum, high VLDL syn-
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thesis, and high levels of oxLDLs both in
circulation and in the lesions of MS and atherosclerosis patients.
Diet, therefore, plays a role in the etiology
and course of MS. A diet high in terrestrial
animal fat and/or carbohydrates leads to a
modulation of PPARs, which can then lead
to MS in the presence of an inflammatory
trigger, whether pathogen or trauma.
the role of lipid metabolism and the
ppars in ms cns inflammation
Permeability of the Blood Brain Barrier
MS patients have severe vascular abnormalities that reduce brain blood flow. These
vascular abnormalities are in fact part of the
feedback loop of the dysregulation of lipids
and inflammatory response of the endothelial macrophages. High levels of circulating
fatty acids and triglycerides have a direct
impact on the vasculature by modifying
the regulatory functions of two main
PPARs: PPAR␤/␦ and PPAR␥ (Duan et
al. 2008).
The expression of the PPAR␤/␦ in the
brain regulates the integrity of the BBB by
controlling the VAP-1 adhesion molecules,
enhancing angiogenesis and vascular repair
(Hall et al. 2008; Ehrenborg and Krook
2009; Haider et al. 2011). Deficient expression of PPAR␤/␦, induced by elevated levels
of free fatty acids in the serum, results in
impaired vascular repair, diminished vascular flow, a reduced hyperplastic development
of microvasculature, and dysregulation of
the VAP-1 adhesion molecules, inducing
more rolling monocytes to enter the layers of
the endothelium (Hall et al. 2008). A deficient PPAR␤/␦ also decreases nuclear translocation of CREB in endothelial cells, thus
accelerating smooth cell proliferation and
the narrowing of blood vessels (Sue et al.
2009). The cerebrovascular dysfunction resulting from PPAR␤/␦ underexpression is
compounded by dysregulation of PPAR␥ activation, which increases the expression of
endothelin-1 (ET-1), a potent vasoconstrictor and regulator of vascular smooth muscle
cell (VSMC) proliferation, and downregulation the main vasorelaxant, nitric oxide
(NO) (Duan et al. 2008).
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Finally, lack of PPAR␤/␦ and PPAR␥ activation also leads to the increased expression
of inflammatory genes, increasing endothelial inflammation (Duan et al. 2008; Hall et
al. 2008; Varga et al. 2011). The evidence
shows that modulation of the PPARs in a dysregulated lipid metabolism makes the endothelial layers more permeable, further leaking
oxLDLs and rolling monocytes across the
blood brain barrier, leading to an inflammatory loop as described below.
Inflammatory Process of the CNS
The normal course of an inflammatory response is a careful balance between the recruitment of: a) lipids from diet, adipocytes, and
energy production to the site of inflammation/injury; and b) cytotoxic macrophages that
produce proinflammatory cytokines and free
radicals, and phagocytic macrophages that remove pathogens, debris, and apoptotic cytotoxic macrophages.
The microglia maintain a highly active
monitoring state in normal, noninflammatory conditions (Nimmerjahn et al. 2005;
Wake et al. 2009). Through the expression
of proteinase activated (PAR) and purinergic receptors (PR), microglia can sense environmental cues such as vascular depression
in the BBB and adenosine triphosphate
(ATP) in damaged cells (Carson et al. 2004;
Wake et al. 2009). Stimuli such as trauma,
pathogens, and even psychological stress induce the microglia to produce proinflammatory enzymes such as free radicals, and
pathogen-inhibiting cytokines and chemokines (Davalos et al. 2005; Chen et al. 2010).
Phagocytic microglia, and T cells, then remove pathogens and debris from the CNS
and undergo a self-regulated apoptotic
mechanism to prevent injury to the CNS from
their own proinflammatory enzymes (Rock et
al. 2004; Drew et al. 2008; Allen and Barres
2009).
In MS, the disequilibrium of lipid homeostasis leads to an imbalance between the cytotoxic and the phagocytic microglia/T cells.
Since oxLDLs circulate in high concentration and cross the BBB, the microglia are
chronically activated into cytotoxic cells in a
feedback loop, where excess of circulating oxLDLs leads to inflammation, producing
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more oxLDLs. Permanently highly activated, the glial cells lack the self-regulatory
apoptotic mechanism that would prevent an
accumulation of toxic foam cells, and neurodegeneration.
The activation of cytotoxicity in microglia,
through the NF-B, JAK-STAT, and MAPK
signaling pathways, induces the expression
of immune response genes responsible for
the release of chemoattractant cytokines,
such as IL-1, IL-6, TN-␣, IFN-␥, and TNF-␣, as
well as small lipid molecules such as the leukotrienes and prostaglandins, reactive oxygen species (ROS) and chemokines (Hoon
Lee et al. 2005). This acute-phase response
induces the liver to produce the C-reactive
protein (CRP), the serum amyloid A (SAA),
as well as fibrinogen and plasminogen activators. During inflammation, the microglia
express MHC class-I/II proteins, thereby becoming effective recruiters of T cells that
then fulfill a variety of roles, from forming an
immune memory, to becoming cytotoxic
(Davalos et al. 2005; Nimmerjahn et al. 2005;
Wake et al. 2009; Chen et al. 2010). The
expression of MHC class-II proteins by activated microglial cells explains the strong association of MS to allelic variants in the HLA
DR and DQ complexes of MHC (Tienari et
al. 2006; Svejgaard 2008; Ramagopalan et al.
2009; Isobe et al. 2010). The variants provide
stronger ligands for microglia to recruit potentially cytotoxic T cells than wild-type alleles.
Activation of the inflammatory response
of microglia is intricately tied to the metabolism of lipids. The acute inflammatory response generates a shift from lipid storage to
lipid sequestration by the immune system.
Most of these changes can be traced to the
transcription of genes regulated by the nuclear PPAR receptors. Activation of PPARs
prevents activation of the proinflammatory
enzymes produced by the microglia and T
cells (Cosulich et al. 2000; Rusyn et al. 2000;
Hoon Lee et al. 2005; Paintlia et al. 2006).
Downregulation of all three PPARs precludes the inhibition of the expression of the
inflammatory response proteins and pathways (see Tables 1, 2, and 3 for a complete list):
nuclear factor-B (NF-B), acute phase C reactive protein, IL-6, monocyte chemoat-
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tractant protein-1 (MCP-1), plasminogen
activator inhibitor-1, soluble CD40 ligand, matrix metalloproteinase-9 (MMP 9),
and cyclooxygenase 2 (COX-2) (Yang and
Frucht 2001; Kota et al. 2005; Collino et al.
2006; Fruchart 2007; Barish et al. 2008; Bishop-Bailey and Bystrom 2009; Wagner and
Wagner 2010).
The consequences of individual PPAR
downregulation are also relevant to MS
pathogenesis. Downregulated PPAR␤/␦ prevents the release of the B-cell lymphoma
(BCL-6) protein, thus reducing the expression of regulator of G-protein signaling (RGS)
genes, which leads to the releasing of the
signal transduction of chemokine receptors, thereby increasing inflammation (Barish et al. 2008). PPAR␥ activation induces the
expression of the suppressor of cytokine signaling protein-3 (SOCS-3), the negative
regulator of the inflammatory response of
the immune system in the CNS (Qin et al.
2007). Downregulation presumably leads to
overexpression of the SOCS-3-regulated inflammatory pathways. Activation of PPAR␥ results in apoptosis of the cytotoxic microglia.
Without such activation (e.g., by a lack of
PPAR␥-ligand interaction), apoptosis does not
happen, leading to an accumulation of cytotoxic macrophages (Harris and Phipps 2001;
Yang and Frucht 2001).
Thus, the activation of microglial cells
leads to the recruitment of monocytes and
helper T cells, which quickly become cytotoxic, but further, are not evacuated either
through an apoptotic mechanism, or by
phagocytosis. Instead, the microglial cells become toxic foam cells and, together with
memory-formed and cytotoxic T cells, release
free radicals, chemoattractant inflammatory cytokines, and chemokines, and indiscriminately
uptake phospholipids from adjacent myelin
sheaths, leading to neurodegeneration.
Oxidative Damage of the CNS and
Impaired Remyelination
The degradation of myelin is connected to
the dysregulation of PPARs and lipid homeostasis because it results, in part, from
indiscriminate phospholipid endocytosis
by the scavenger receptors on macrophages
(above), accumulation of cytotoxic foam
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cells and low peroxisome proliferation in the
CNS and liver cells, leading to oxidative damage and impaired myelin synthesis. This
mechanism of myelin degradation is distinct
and contradicts the hypothesis of molecular
mimicry leading to erroneous immune attack (Blewett 2010).
Myelin synthesis in the CNS is concentrated in the peroxisomes of oligodendrocytes, and is also found in the peroxisome of
other CNS cells. The peroxisomes play a
dual role of maintenance and synthesis of
myelin: they are necessary for the compaction and biogenesis of the myelin sheath by
regulating oligodendrocyte differentiation
and posttranslational modifications of myelin proteins, such as the myelin oligodendrocyte glycoprotein (MOG), the proteolipid
protein (PLP), and the myelin basic protein
(MBP) (Hall et al. 2008; Bishop-Bailey and
Bystrom 2009; Wagner and Wagner 2010); to
protect the axons by inhibiting the release of
hydrogen peroxides by catalase and the trapping action of uric acid (Massa et al. 2009);
and by ␤-oxidation of the neuroinflammatory leukotrienes, prostaglandins, and very
long chain of fatty acids (VLCFA) (Baes and
Aubourg 2009). The maintenance and protection of the CNS is not confined to the
peroxisome of the CNS cells, but extends to
the liver peroxisomes. Deficiency of liver peroxisomes causes myelin anomalies at the ultra and inner structural levels of the axons,
severe gliosis (activation of glial cells), a toxic
VLCFA accumulation in the brain and the
spinal cord, as well as a higher concentration
of peroxynitrite that is no longer contained
due to the low synthesis of uric acid by the
disabled organelle (Hulshagen et al. 2008;
Dujmovic et al. 2009).
The crucial importance of wholeorganism peroxisomal metabolism in
maintaining the integrity of the CNS is
well illustrated by the numerous neurodegenerative and demyelinating diseases in
which either the whole organelle or a single
mechanism is faulty (Hulshagen et al. 2008;
Baes and Aubourg 2009). In MS, damage to
the CNS is further compounded by lack of
remyelination associated with the regulatory
functions of nuclear receptors and, in particular, the expression of the retinoid receptor,
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RXR. Specifically, downregulation of RXR␥
reduces maturation of oligodendrocytes in
areas of active remyelination (Hanafy and
Sloane 2011). The role of lipid metabolism
and nuclear receptors in maintaining the integrity of the CNS is therefore fivefold: 1)
maintain the integrity of the blood brain barrier; 2) prevent the activation of proinflammatory pathways; 3) regulate the apoptosis of
cytotoxic T and microglial cells; 4) regulate
the number and efficiency of peroxisomes in
both CNS and liver cells; and 5) regulate the
maturation of oligodendrocytes and myelin
synthesis. All five regulatory pathways are impaired in MS, through the mechanisms of
lipid dysregulation described so far.
the role of lipid metabolism and the
ppars in low vitamin d: the northern
high latitudes as trigger of ms
Vitamin D has been at the center of MS
research because it links areas of high MS prevalence in the high northern latitudes where
lack of sunlight reduces UV-linked Vitamin D
synthesis with immune system regulation
(Poser 1994; Rosati 2001; VanAmerongen et
al. 2004; Broadley 2007; Oksenberg et al.
2008; Ascherio et al. 2010; Comabella et al.
2010; Grant 2010; Simon et al. 2010; van der
Mei et al. 2011; Wang et al. 2011). But steroidogenesis, including the synthesis of active Vitamin D, is also intricately linked to
lipid metabolism through diet. Low levels of
exogenous polyunsaturated fatty acid in serum slow the regulatory function of PPARs,
in particular PPAR␣ and PPAR␥, on the production of calcitriol (1,25(OH)2D3), the bioactive form of Vitamin D. PPAR␥ activated by
PUFAs decreases the expression of SREBP-1c
and increases expression of the microsomal
cytochrome p450 27B1 (CYP27B1 25hydroxyvitamin D3 1-␣-hydroxylase), which catalyzes calcidiol to calcitriol (Li et al. 2011;
Wang et al. 2011). Low expression of
CYP27B1 in dendritic cells inhibits brain development (Eyles et al. 2005), and is consistent with the observed low calcitriol profile
of MS patients (VanAmerongen et al. 2004).
PPAR␣ also serves as a coregulator of the
Vitamin D receptor (VDR), which recruits
and heterodimerizes with the RXR␤ dimer
to synthesize calcitriol de novo (Savkur et
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al. 2005; Sertznig et al. 2009). More
1,25(OH)2D3 increases the expression of the
Vitamin D receptor (VDR) and its heterodimerization with RXR␤ to synthesize
more calcitriol in a loop. Therefore, an environment low in PUFAs results in a broken
loop where the downregulation of the
PPARs on steroidegenesis leads to low levels
of calcitriol, both through low heterodimization of the VDR to RXR, and decreased biogenesis.
This explains why the environmental risk
to develop MS in populations residing in the
high northern latitudes is not evenly spread,
but concentrated among populations with
specific diets (Tienari et al. 2006; Ascherio
and Munger 2007; Ascherio et al. 2010).
Low-levels of UV-linked Vitamin D synthesis,
compounded by a diet rich in triglycerides,
carbohydrates, and low in PUFAs, are the
environmental triggers. The coastal Norwegian communities, whose diet has traditionally been poor in triglycerides and
carbohydrates, but high in PUFAs and
Vitamin D3 fish oil, showed a relatively low
incidence of MS compared with their inland
and Swedish counterparts until the 1980s.
Since then, dietary changes toward a higher
intake of terrestrial animal triglycerides and
carbohydrates paralleled a threefold rise in
the incidence of MS in Norway (Midgard et
al. 1991).
the role of lipid metabolism and the
ppars in ms muscular atrophy
Muscle atrophy, weakness, and spasticity,
all major pathophysiological consequences
of MS, can also be understood in the context
of a dysregulation of lipid homeostasis and
the regulatory function of the nuclear receptors, more specifically downregulation of
PPAR␤/␦ (Tilbery et al. 1989; Haselkorn and
Loomis 2005; Dalgas et al. 2009). PPARs
have distinct roles in muscle cells by increasing fatty acid catabolism, cholesterol efflux,
and energy expenditure of the muscles
(Dressel et al. 2003; Ehrenborg and Krook
2009). The expression of PPAR␤/␦ increases
with elevated levels of free fatty acids in serum, and also muscle activity (Lunde et al.
2007). This may explain the recent findings
that MS patients improve their motor ability
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through resistance-training exercises (White
et al. 2004; Dalgas et al. 2009; De SouzaTeixeira et al 2009).
Another mechanism linking muscle atrophy and spasticity to PPAR regulatory function is the synthesis of creatine. Creatine is a
major component of muscle development.
Altered PPAR␥ expression has been observed to inhibit myogenic differentiation in
skeletal muscle cells, and impair the synthesis of creatine (Singh et al. 2007). This is
further confirmed by lower levels of the creatine breakdown product, creatinine, observed
in both MS and diabetes 2 type patients. The
lack of creatine synthesis results in muscle atrophy and reduced renal function in both diseases (Calabresi et al. 2002; Calkin et al. 2006).
ppars, homocysteine, lipid
metabolism, and sex disparity in ms
Women are twice as likely to develop MS,
and autoimmune diseases in general, while
men are more likely to develop atherosclerosis at an earlier age than women. Sex affects the
prevalence, pathological course, and severity
of the disease (Greer and McCombe 2011).
Biological differences in males and females,
such as the differences in immune system
response, morphology of the CNS, and other
factors indubitably play a role in both the
etiology and course of the disease. However,
each of these factors and its effects has been
studied as separate entities within the autoimmunity hypothesis. This framework has
not linked all of the factors into one coherent mechanistic explanation of the sexual
disparity seen in MS. The proposed framework can explain the sex disparity in MS
prevalence in terms of the central functions
of PPAR␣ in lipid metabolism and homocysteine synthesis.
Homocysteine (Hcy), a sulfur-containing
amino acid, is formed from the metabolism
of methionine, an essential amino acid acquired through diet, particularly from food
rich in protein, and certain cereals and
seeds, such as sesame. This amino acid is
metabolized as a derivative of the methionine cycle in two ways: through remethylation or transsulfuration. Homocysteine is
formed by the addition of a methyl group
from methionine, and reconverted into me-
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thionine, through the Vitamin B12 pathway,
in which Vitamin B12 act as a cofactor of
methionine synthase, and folates act as coenzymes (Fukagawa et al. 2000). When levels of
methionine are too high, homocysteine is
metabolized into cysteine by entering the transsulfuration pathway, in which Vitamin B6 acts
as cofactor for cystathionine ␤-synthase and cystathionine ␥-ligase. Excessive levels of homocysteine are correlated with low Vitamin B6,
Vitamin B12, folic acid, and low levels of
creatinine (Sassi et al. 2002). High levels
of Hcy have also been correlated with the
risk of developing cardiovascular diseases, strokes, restenosis, and high oxidative stress, and are found in the plasma
and lesions of both MS and atherosclerosis patients (Besler and Comoğlu 2003;
Schwarz and Leweling 2005; Ramsaransing et al. 2006).
Sexual disparity in homocysteine levels
can partially explain sexual disparity in both
MS and atherosclerosis. The rate of synthesis
of homocysteine is higher in men than in
young women. Both sexes, however, steadily
develop higher levels of Hcy with increasing
age (Bostom et al. 1999; Sassi et al. 2002;
Hayden and Tyagi 2004). The mechanism
underlying differential rates of Hcy synthesis
is still debated, but several hypotheses
have been put forward to explain it. Methionine synthesis differs in men and
women because the sexes may have different
demands for methyl groups (Mudd and Poole
1975; Fukagawa et al. 2000). A greater rate of
methionine transamination and more rapid
methionine cycle in which homocysteine is
both remethylated and diverted to cystathionine in premenopausal women has been
linked to lower levels of homocysteine, and
protection against vascular disease (Fukagawa et al. 2000).
Sex hormones influence homocysteine
concentrations. In particular, estrogen lowers the concentration of homocysteine in
plasma, which explains both the sexual disparity in producing Hcy, but also why women
develop higher levels of Hcy with increasing
age, and more markedly after menopause
(Fukagawa et al. 2000; Sassi et al. 2002). Sex
differences in lipid metabolism and levels of
homocysteine are also linked by the transsul-
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furation of homocysteine into cysteine, which
requires the amino acid serine, and occurs at a
higher rate in women than in men (Elshorbagy et al. 2008). Serine is generated from
intermediates of glycolysis that are regulated
by the PPARs (Herzig et al. 2003; Davidson
2006; Sue et al. 2009). Dysregulation of
PPAR functions would result in less serine,
and more homocysteine, both phenomena
observed in MS patients, and would also be
more marked in young women, since they
tend to have a faster methionine cycle. A
reduction of serine levels would also produce lower levels of sphingolipid synthesis,
and impair the synthesis of myelin (Inuzuka
et al. 2005). The effects of low serine levels
are compounded by myelin synthesis requiring a methyl group from S-adenosylmethionine of the methionine cycle to
synthesize methylarginine incorporated into
myelin basic protein (MBP) (Small et al.
1981). PPAR␣ increases the expression of
methionine-adenosyltransferase (MAT),
which synthesizes methionine into Sadenosylmethionine (Luc et al. 2004). Thus,
there is a secondary negative effect of a dysfunctional PPAR␣: a slower production of
S-adenosylmethionine, leading to a dysfunctional myelin synthesis. Higher levels of homocysteine are also associated with higher
oxidative stress, in particular in the CNS,
which would compound the impaired myelin synthesis with an increased inflammatory
response in the cells of the CNS (Hunt and
Tyagi 2002; Hayden and Tyagi 2004; Yilmaz
et al. 2005; Jiang et al. 2007).
An additional link between high levels of
homocysteine and the metabolism of lipids is
in the interaction of homocysteine and Apo
AI synthesis (Devlin and Lentz 2006). High
levels of homocysteine inhibit the expression
of PPAR␣-regulated Apo A1, leading to a
lower production of HDL and a lower lipolysis of VLDL (Mikael et al. 2006). Homocysteine may also impair PPARs by acting as an
inhibitory ligand (Hayden 2008).
Dysfunction of the PPAR␣, therefore, is at
the center of sexual disparity in lipid metabolism, and the risk of developing MS. PPAR␣
mediates sexual dimorphism in lipid metabolism, specifically in the regulation of fatty
acid oxidation in the liver (Jalouli et al. 2003;
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Ciana et al. 2007). This sexual dimorphism
underlies women having a higher removal
efficiency of VLDL-triglyceride from circulation, but a greater hepatic VLDL-triglyceride
secretion rate; and men having a lower
VLDL-triglyceride secretion rate, but also
lower removal rate from the serum (Magkos
and Mittendorfer 2009). The expression of
PPAR␣ is controlled by hormone levels, and
is significantly higher in the livers of men
than in those of women, partly explaining
sexual dimorphism in lipid metabolism (Jalouli et al. 2003). Dunn et al. showed that
PPAR␣ is also expressed at higher levels in
male than female mice T cells, and that deficiency of the PPAR␣ gene selectively affects
male T lymphocytes (Dunn et al. 2007).
Males have a higher expression of PPAR␣ in
naive T cells (Th2), while females have a
higher expression of PPAR␣ in activated T
cells (Th1). This disparity increases immune
response and correlates to both the more robust immune system response known in
women, and the greater likelihood of women
to develop MS and other autoimmune diseases
(Dunn et al. 2007; Voskuhl 2011). Male but
not female PPAR␣-deficient mice developed
more severe experimental autoimmune encephalomyelitis (EAE), the animal model of
MS (Dunn et al. 2007). A similar sexual difference in the course of the disease is noted
in MS patients (Greer and McCombe 2011).
Here again, the PPARs act as central
nodes between lipid metabolism and the immune system. A dysregulation of PPAR␣
would be deleterious in different ways for
both sexes. High levels of homocysteine in
men have a greater tendency to impact the
artery walls by concentrating the amino acid’s oxidative action on the endocardial endothelial cells, letting in more oxLDLs in the
intima of the endothelium (McCully et al.
1990; Nygård et al. 1997; Hunt and Tyagi
2002; Jiang et al. 2007). In women, the impaired production of serine by sluggish
PPAR function and a slower transsulfuration
pathway translates into weakened components of the CNS, which is highly dependent
on the methionine cycle methyl groups for
maintenance (Small et al. 1981; Fukagawa et
al. 2000). The influence of sexual hormones
on both the concentration of homocysteine
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and elements of lipid metabolism that are
regulated by the PPARs, further accentuates
the disparity between men developing atherosclerosis and women developing MS (Williams 2004; Magkos and Mittendorfer 2009;
Marinou et al. 2011). These mechanisms are,
however, not exclusive to either sex.
More studies are needed to explain the
mechanisms underlying sexual disparity in
MS. Understanding the disease as a metabolic, rather than immune, disorder provides a unifying framework for every known
aspect of sexual dimorphism in MS, and may
explain differential prevalence of autoimmune diseases generally.
Discussion
The human diet has changed dramatically
since the advent of industrialized agriculture
and food processing. In 50 years, we have
moved to a diet high in carbohydrates and
terrestrial animal fat, with well-known health
consequences: rise in cardiovascular and
metabolic diseases. Autoimmune diseases
have also increased over the same time span.
Hypotheses linked to the autoimmune hypothesis, such as the “hygiene hypothesis,”
which suggests that reduced exposure to critical microorganisms has led to autoimmune
disorders (Rook 2009), lack a unifying
framework for all elements of the pathophysiology, genetic, and environmental triggers
of MS. Lack of exposure to pathogens, or
exposure to specific pathogens, are logically
contradictory explanations for the rise in MS
prevalence.
The new approach to understanding MS
pathogenesis explains both the recent rise in
incidence and all pathological, genetic, and
environmental aspects of the disease. The
homeostasis of lipid metabolism, regulated
in great part by the PPARs, and already weakened by environmental factors such as low
Vitamin D, a high fat/high carbohydrate
diet, and/or defective alleles in the PPAR or
PPAR-controlled genes, collapses during
acute-phase response triggered by a pathogen, trauma, or stress. Modulation in the
regulatory functions of PPARs in reaction to
the acute-phase response starts a chain reaction. Reduced fat storage, enhanced lipolysis, higher fatty acids oxidation in both the
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liver and muscles, and boosted secretion of
de novo fatty acids and VLDLs by the liver,
leads to increased levels of oxLDLs in the
serum. High levels of oxLDLs circulating in
the serum and across the blood brain barrier
are controlled either by saturated macrophage apoptosis or by transport to the liver
by HDL. But faulty PPAR regulation of both
the intake and efflux of oxLDLs in peripheral microglial cells leads to the overloading
of the cells with toxic lipids and the formation of cytotoxic cells. Excess of oxLDLs, now
boosted by the acute-phase response de novo
lipid synthesis, increases differentiation of
rolling monocytes into microglial cells, and
sluggish PPAR regulation decreases smooth
cell proliferation and angiogenesis, weakening
the blood brain barrier. The anti-inflammatory
response activated by lipid-laden microglia,
and mediated by damaged PPARs, also causes
more recruitment of helper T cells, which will
both form a memory of the oxLDL-laden
microglia cell membranes and become cytotoxic cells through the release of free radicals. Both lipid-laden microglial cells and T
cells differentiate into cytoxic foam cells emitting free radicals, and indiscriminately attack
cell membranes that contain phospholipids.
The apoptotic process of removing the oxidized toxic cells is rendered inoperative by the
downregulation of the TGF and AP-1 pathways
by sluggish PPARs (PPAR␥ and ␤/␦), leading
to foam cell stagnation and the formation of
plaques that damage the phospholipid-rich
myelin sheath of adjacent axonal neurons. The
repair of the myelin sheath is impaired by a
lack of peroxisome functionality in oligodendrocytes, leading to a sluggish ␣- and ␤-oxidation and a toxic accumulation of nonoxidized
very long chain of fatty acids in those cells. The
now weakened and permeable blood brain
barrier lets in more oxLDLs, which generates
an inflammatory response in the peripheral
microglia, sending a signal to the liver to synthesize more lipids that will become oxLDLs,
in a loop-like mechanism (see Figure 4).
This proposed mechanism underlines the
similarity between atherosclerosis and multiple sclerosis, and explains how both genetic
and environmental triggers lead to the development of multiple sclerosis. A diet high in
animal lipids and carbohydrates, which char-
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acterizes the diet of industrialized countries
for the past 50 years, compounded by environmental factors such as a low availability of
sunlight, and genetic factors linked to the
PPAR regulatory functions in lipid homeostasis
and the immune system, represent a high risk
background for populations to develop MS.
This new framework explains the origins of
all the symptoms of MS studied here, from
restenosis, neurological disorders, and muscle
spasticity to weight loss at the onset of the disease and shift of lipid metabolism throughout
the course of the disease and during acute
relapses.
Conclusion
MS should be approached as a dysregulation of the homeostatic system, where dysregulation of one element in the regulation of
lipid metabolism leads to a cascade involving
inflammation and impairment of reparative
mechanisms. The pathogenesis of atherosclerosis and MS are similar in the dyresgulation of
lipid homeostasis, and sex-specific differences in lipid metabolism lead to the sex
disparity in prevalence of each disease. Multiple sclerosis should be thought of as a
metabolic disease, the female equivalent
of atherosclerosis, not as a disease of the
immune system. When lipid homeostasis is
no longer maintained, it leads to a cascade of
similar events that predominantly lead to
atherosclerosis in men, and in women leads
to MS, while excluding neither sex from developing the other disease.
This framework explains why statins and
PPAR agonists (fibrates) have shown so much
promise in treating MS (Stüve et al. 2003; Sena
et al. 2007; Xu et al. 2007; Drew et al. 2008;
Goldman and Cohen 2008; MalchiodiAlbedi et al. 2008). A cure for MS will not be
achieved by taking one or the other, or both,
in a symptom-by-symptom approach, but by
modulating the effects of both medications
in order to reestablish the homeostasis of the
lipid metabolism. To fully understand the influence of PPARs on MS and its therapy will
require much more work. Initiatives such as
the nuclear receptor signaling atlas (NURSA)
are essential to this endeavor (McKenna et al.
2009). The new framework presented here
makes a cure for MS closer than ever.
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